Small Trial Results: Hydroxychloroquine Effective For COVID-19 Treatment

Small Trial Results: Hydroxychloroquine Effective For COVID-19 Treatment


1
404
https://www.veteranstoday.com/wp-content/uploads/COVID-19_001-320x140.jpg 320w, https://www.veteranstoday.com/wp-content/uploads/COVID-19_001-640x2... 640w, https://www.veteranstoday.com/wp-content/uploads/COVID-19_001-768x3... 768w" sizes="(max-width: 1000px) 100vw, 1000px" alt="" title="COVID-19_001" />

HCQ Effective for COVID-19 in Small Randomized Trial

by Molly Walker, Associate Editor, MedPage Today

Hospitalized patients in China with COVID-19 coronavirus treated with hydroxychloroquine (HCQ), an antimalarial also used to treat autoimmune diseases, had a shorter time to clinical recovery, as well as improved pneumonia, a randomized trial found.

Patients randomized to receive hydroxychloroquine with standard treatment had a significantly shorter time to body temperature recovery of about a day, as well as a significantly reduced time to cough remission of about a day versus patients receiving only standard treatment, reported Zhan Zhang, MD, of Wuhan University in China, and colleagues.

Moreover, a larger proportion of patients in the HCQ group had improved pneumonia compared with patients in the control group (80.6% vs 54.8%), they wrote in a manuscript posted on the medRxiv preprint server.

HCQ and chloroquine for COVID-19 treatment have been in the spotlight ever since President Trump first touted their benefits in a press briefing 2 weeks ago. The FDA said it was looking into conducting randomized trials of the drug in COVID-19 patients, though some hospitals have already opted for off-label use of these agents.

One person in Arizona died after ingesting chloroquine phosphate, also sold for cleaning fish tanks, prompting the CDC to issue a warning against this practice.

Previous trials had explored in vivo activity of the drug, and one pilot study found no benefit in clinical measures or viral clearance compared with standard of care.

Still, the drug continues to be tested in ad hoc trials, including this one by Zhang and colleagues. They randomized 62 patients hospitalized with laboratory-confirmed COVID-19 infection in February. All patients received standard treatment, including oxygen therapy, antiviral agents, antibacterial agents, and immunoglobulin, with or without corticosteroids; patients in the intervention group also received oral HCQ sulfate tablets 400 mg/day on days 1-5.

Primary endpoint was time to clinical recovery, defined as “return to body temperature and cough relief, maintained for more than 72 [hours].” Mean patient age was about 45 and almost half were men, with no significant differences in the age and sex distribution between groups, the authors said.

Patients in the HCQ group had a significantly shorter time to body temperature recovery versus controls (2.2 days vs 3.2 days, P=0.0008). Similar results were seen for time to cough remission for the HCQ and control groups (2.0 vs 3.1 days, P=0.0016).

They noted four of 62 patients progressed to severe illness, all in the control group.

Two patients reported mild adverse reactions in the HCQ group, one with a rash and one with a headache.

Retinopathy is a known side effect of long-term therapy with HCQ — often seen in lupus patients who may stay on the drug for years — and patients occasionally experience arrhythmias and, more rarely, gastrointestinal reactions, cramps, and liver dysfunction. Patients should be monitored for these, but “short-term application of HCQ is relatively safe,” Zhang and colleagues wrote.

While acknowledging a need for large-scale clinical trials and other research to clarify the specific treatment mechanism and optimize the treatment plan, the authors concluded that “considering that there is no better option at present, it is a promising practice to apply HCQ to COVID-19 under reasonable management.”

Disclosures

This study was supported by the Epidemiological Study of COVID-19 Pneumonia to Science and Technology, Department of Hubei Province.

Zhang and co-authors disclosed no relevant relationships with industry.

Views: 11

Comment

You need to be a member of 12160 Social Network to add comments!

Join 12160 Social Network

Comment by stormtruther on April 2, 2020 at 6:59am

Scientists, however, warn about raising false hopes and say major studies are needed to prove the drugs are safe and effective against coronavirus

https://au.news.yahoo.com/the-controversial-drug-approved-to-fight-...

lamestream are against it ...everything they say is bullshit....therefore it probably works, deductive reasoning Dr Watson

Comment by stormtruther on April 2, 2020 at 6:52am

#9 Wormwood

Artemisinins are derived from extracts of sweet wormwood (Artemisia annua) and are well established for the treatment of malaria, including highly drug-resistant strains.

Artemisinins reduce replication rates of a host of different viruses. Artesunate is effective at stopping viral replication in 100mg per day oral doses (R).

https://men-elite.com/2020/03/13/coronavirus-the-truth-about-the-vi...

Drink Absinth and be merry, I just happen to have one in the yard because i like the buzz....two for the price of one

"Destroying the New World Order"

TOP CONTENT THIS WEEK

THANK YOU FOR SUPPORTING THE SITE!

mobile page

12160.info/m

12160 Administrators

 

Latest Activity

Doc Vega posted a blog post

The Cancel Culture Vulture

  Better to shut them down than hear their point of viewCancel culture coming after youHelping to…See More
yesterday
Doc Vega posted a photo
Friday
Doc Vega posted a blog post

The Fingerprint

The Fingerprint On a dance with the unpredictability of the signals you sendA solemn pact with my…See More
Friday
Sandy posted a video
Friday
tjdavis posted a video
Thursday
Burbia replied to Burbia's discussion Trump Receives Marching Orders
Wednesday
Less Prone favorited Burbia's video
Wednesday
Less Prone replied to Burbia's discussion Trump Receives Marching Orders
"Bullets can be effective in reinforcing ownership."
Wednesday
Burbia posted a discussion

Trump Receives Marching Orders

Netanyahu has made 3 visits to the White house since Trump's second term as President of the United…See More
Wednesday
Burbia commented on Burbia's video
Thumbnail

Ben Shapiro Just LOST HIS MIND — There's No Coming Back From This

"Omg. The Ben Shapiro voice that Luke is imitating here couldn't be any more comedic to…"
Tuesday
Burbia posted a video

Ben Shapiro Just LOST HIS MIND — There's No Coming Back From This

Get the magnesium your body needs - https://wearechange.shop/product/magnesium-glycinate/Ben Shapiro Just LOST HIS MIND — There's No Coming Back From ThisHig...
Tuesday
cheeki kea posted photos
Jul 8
Doc Vega posted blog posts
Jul 7
Burbia posted a video

A few reasons I don’t like jews. It’s not complicated.

These are the reasons I became antisemitic. It’s not complicated. Sure, I could go on for days, weeks, months outlining everything, but I don’t need to. This...
Jul 6
Doc Vega commented on Doc Vega's blog post Unusual Discoveries and Headlines
"Less Prone, Thanks Buddy! I'd like to volunteer as a historical reconstructionist! "
Jul 6
Less Prone left a comment for t.me/TheIntelligenceLibrary
"Welcome to a revolutionary concept in public communication, the truth."
Jul 6
pohonemas33 team is now a member of 12160 Social Network
Jul 6
Less Prone favorited cheeki kea's discussion Tartaria
Jul 6
tjdavis's 2 blog posts were featured
Jul 6
Doc Vega's 7 blog posts were featured
Jul 6

© 2025   Created by truth.   Powered by

Badges  |  Report an Issue  |  Terms of Service

content and site copyright 12160.info 2007-2019 - all rights reserved. unless otherwise noted